+44 20 8123 2220
info@marketpublishers.com

Stargardt Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

https://marketpublishers.com/r/SAB61DDDEC12EN.html
Date: May 2024
Pages: 129
Price: US$ 6,499.00 (Single User License)
ID: SAB61DDDEC12EN

Abstracts

The 7 major Stargardt disease markets are expected to exhibit a CAGR of 22.82% during 2024-2034.

The Stargardt disease market has been comprehensively analyzed in IMARC's new report titled "Stargardt Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Stargardt disease refers to an inherited single-gene disorder that affects the retina, which is the part of the eye that detects light and sends visual information to the brain. The ailment is characterized by macular degeneration that begins in childhood, adolescence, or adulthood, causing progressive loss of vision. The primary symptom of the disease is a decrease in visual acuity, which cannot be corrected with glasses. This manifests as a diminished ability to see fine details while viewing or reading distant objects. Various other common indications associated with Stargardt disease include wavy vision, blurriness, blind spots, loss of depth perception, impaired color vision, sensitivity to glare, difficulty adapting to dim lighting, etc. The diagnosis of the condition is mainly made through clinical features, medical history, and an eye examination via slit lamp. The healthcare provider may also perform genetic testing to ensure the presence of genome abnormalities within the body. Numerous diagnostic tools, such as spectral-domain optical coherence tomography, microperimetry, electroretinography, etc., are utilized in patients to confirm a diagnosis and rule out other possible causes.

The increasing prevalence of genetic disorders caused by mutations in one of several genes involved in the processing of vitamin A in the retina is primarily driving the Stargardt disease market. In addition to this, the widespread adoption of intravitreal vasodilators, including dobesilate, that inhibit overexpression of fibroblast growth factor

+44 20 8123 2220
info@marketpublishers.com

and improve visual acuity in patients is also bolstering the market growth. Furthermore, the inflating application of fluorescein angiography for diagnosing various ocular pathologies by assessing the anatomy and physiology of retinal and choroidal circulation is acting as another significant growth-inducing factor. Apart from this, the escalating demand for vision rehabilitation therapy to treat the ailment, since it can maximize visual functioning and improve the quality of life for patients, is further creating a positive outlook for the market. Moreover, the emerging popularity of gene replacement therapy, which works by replacing the incorrect gene variant with the correct version, thereby enhancing the body's ability to fight the condition, is expected to drive the Stargardt disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Stargardt disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Stargardt disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Stargardt disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain

+44 20 8123 2220
info@marketpublishers.com

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Stargardt disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Stargardt disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Stargardt disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Stargardt disease market performed so far and how will it perform in the coming years?

+44 20 8123 2220
info@marketpublishers.com

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Stargardt disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Stargardt disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Stargardt disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Stargardt disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Stargardt disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Stargardt disease across the seven major markets?
What is the size of the Stargardt disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Stargardt disease?
What will be the growth rate of patients across the seven major markets?

Stargardt Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Stargardt disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Stargardt disease market?
What are the key regulatory events related to the Stargardt disease market?

+44 20 8123 2220
info@marketpublishers.com

What is the structure of clinical trial landscape by status related to the Stargardt disease market?
What is the structure of clinical trial landscape by phase related to the Stargardt disease market?
What is the structure of clinical trial landscape by route of administration related to the Stargardt disease market?

+44 20 8123 2220
info@marketpublishers.com

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 STARGARDT DISEASE - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 STARGARDT DISEASE - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 STARGARDT DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights

+44 20 8123 2220
info@marketpublishers.com

7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)

+44 20 8123 2220
info@marketpublishers.com

7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 STARGARDT DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 STARGARDT DISEASE - UNMET NEEDS

10 STARGARDT DISEASE - KEY ENDPOINTS OF TREATMENT

11 STARGARDT DISEASE - MARKETED PRODUCTS

11.1 List of Stargardt Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.

+44 20 8123 2220
info@marketpublishers.com

12 STARGARDT DISEASE - PIPELINE DRUGS

12.1 List of Stargardt Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Tinlarebant - Belite Bio
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Emixustat - Kubota Vision
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 vMCO 010 - Nanoscope Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 STG 001 - Stargazer Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Zimura - IVERIC bio
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. STARGARDT DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

+44 20 8123 2220
info@marketpublishers.com

14. STARGARDT DISEASE – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 STARGARDT DISEASE - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
  15.2.1 Stargardt Disease - Market Size
    15.2.1.1 Market Size (2018-2023)
    15.2.1.2 Market Forecast (2024-2034)
  15.2.2 Stargardt Disease - Market Size by Therapies
    15.2.2.1 Market Size by Therapies (2018-2023)
    15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
  15.3.1 Stargardt Disease - Market Size
    15.3.1.1 Market Size (2018-2023)
    15.3.1.2 Market Forecast (2024-2034)
  15.3.2 Stargardt Disease - Market Size by Therapies
    15.3.2.1 Market Size by Therapies (2018-2023)
    15.3.2.2 Market Forecast by Therapies (2024-2034)
  15.3.3 Stargardt Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
  15.4.1 Stargardt Disease - Market Size
    15.4.1.1 Market Size (2018-2023)
    15.4.1.2 Market Forecast (2024-2034)
  15.4.2 Stargardt Disease - Market Size by Therapies
    15.4.2.1 Market Size by Therapies (2018-2023)
    15.4.2.2 Market Forecast by Therapies (2024-2034)
  15.4.3 Stargardt Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
  15.5.1 Stargardt Disease - Market Size
    15.5.1.1 Market Size (2018-2023)
    15.5.1.2 Market Forecast (2024-2034)
  15.5.2 Stargardt Disease - Market Size by Therapies
    15.5.2.1 Market Size by Therapies (2018-2023)

+44 20 8123 2220
info@marketpublishers.com

15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Stargardt Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Stargardt Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Stargardt Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Stargardt Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Stargardt Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Stargardt Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Stargardt Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Stargardt Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Stargardt Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Stargardt Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Stargardt Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Stargardt Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Stargardt Disease - Access and Reimbursement Overview

16 STARGARDT DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 STARGARDT DISEASE MARKET - SWOT ANALYSIS

+44 20 8123 2220
info@marketpublishers.com

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 STARGARDT DISEASE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Stargardt Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: https://marketpublishers.com/r/SAB61DDDEC12EN.html

Price: US$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/SAB61DDDEC12EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com